Attributes | Values |
---|
rdf:type
| |
Description
| - In the MM-015 trial, melphalan - prednisone - lenalidomide followed by lenalidomide maintenance (MPR-R) signifcantly prolonged progression-free survival versus melphalan - prednisone (MP) in newly diagnosed patients with multiple myeloma aged >= 65 years. Health-related quality of life (HRQoL), a secondary endpoint of MM-015, was also improved with MPR-R. This sub-analysis evaluated the impact of individual predictive factors on HRQoL. Patients completed HRQoL questionnaires at baseline, every third cycle and at progressive disease (PD)/treatment discontinuation.
- In the MM-015 trial, melphalan - prednisone - lenalidomide followed by lenalidomide maintenance (MPR-R) signifcantly prolonged progression-free survival versus melphalan - prednisone (MP) in newly diagnosed patients with multiple myeloma aged >= 65 years. Health-related quality of life (HRQoL), a secondary endpoint of MM-015, was also improved with MPR-R. This sub-analysis evaluated the impact of individual predictive factors on HRQoL. Patients completed HRQoL questionnaires at baseline, every third cycle and at progressive disease (PD)/treatment discontinuation. (en)
|
Title
| - Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
- Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial (en)
|
skos:prefLabel
| - Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial
- Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged >= 65 years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial (en)
|
skos:notation
| - RIV/61988987:17110/14:A1501CGB!RIV15-MSM-17110___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/61988987:17110/14:A1501CGB
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Health-related quality of life (HRQoL); lenalidomide; multiple myeloma; minimal important difference (MID); QLQ-C30; QLQ-MY20 (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| |
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Hájek, Roman
- Delforge, Michel
- Dimopoulos, Meletios A.
- Kropff, Martin
- Palumbo, Antonio
- Petrucci, Maria Teresa
- Lewis, Philip
- Mei, Jay
- Millar, Stefanie
- Zhang, Jingshan
|
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |